Skip to content
value.today

FutureWorld: financial analysis

Ratios worked out from 3 fiscal years of FutureWorld's statements, compared with 665 companies in Biotechnology.

The newest statement on file is for fiscal 2014. The figures below describe that year, not FutureWorld today.

FutureWorld scorecard#

Passes 0 of the 5 checks that could be worked out. Fiscal year 2014.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.00 vs -0.00Diluted EPS -0.00 in fiscal 2014 against -0.00 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 1
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2014.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.22 at the end of fiscal 2014.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-2.2×Operating income -2.2 times interest in fiscal 2014.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year70.5%Diluted shares up 70.5% in fiscal 2014.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2014 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Net loss of $2 million, the 3th loss-making year in a row.
  • Free cash flow was negative: -$1 million.
  • The share count rose 70.5% in the year.
  • Shareholders' equity is negative: -$1 million.
  • Operating income covers the interest bill only -2.2 times.
  • Liabilities due within a year exceed current assets (current ratio 0.22).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

2of 5(4 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets rosenot on file
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

FutureWorld: profitability by fiscal year
Fiscal yearTrend201420132012Median of peersAhead of
Return on assets-939.4%——-44.4%0%

Financial strength#

FutureWorld: financial strength by fiscal year
Fiscal yearTrend201420132012Median of peersAhead of
Interest cover-2.16×-14.00×-10.00×-22.77×86%
Current ratio0.22×0.00×—4.39×5%
Equity share of assets-248.5%——64.7%4%

Cash#

FutureWorld: cash by fiscal year
Fiscal yearTrend201420132012Median of peersAhead of
Free cash flow$-1 M——$-40 M86%

Shareholder returns#

FutureWorld: shareholder returns by fiscal year
Fiscal yearTrend201420132012Median of peersAhead of
Change in share count70.5%3.1%—17.3%21%

How each figure is worked out#

Return on assets
Net income as a share of total assets (average of the year).
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Change in share count
Diluted shares against the year before. Negative: fewer shares.

Source: FutureWorld's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that FutureWorld is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to FutureWorld